doi:10.1016/b978-0-12-813014-8.00011-1
Patients taking Wegovy have nearly five times the risk of sudden sight loss of those on Ozempic, a large-scale study has found
Even though obesity is recognised as a complex chronic disease
"Whole Exome Sequencing Reveals the Order of Genetic Changes during Malignant Transformation and Metastasis in a Single Patient with NF1-plexiform Neurofibroma."

Embla coaches work with members to: Set achievable goals and build consistency in daily behaviors Identify and defuse unhelpful thoughts and food-related coping patterns Prepare for plateaus and relapses and navigate through them Develop the confidence and skills to maintain weight loss for life Real-world outcomes: what employers should expect Employers implementing coaching-first models like Embla's can expect: Improved medication efficiency members use lower doses and taper sooner, which reduces total drug spend Higher engagement and adherence weekly video coaching drives strong retention and satisfaction Lower long-term costs less reliance on high-cost GLP-1s, fewer comorbidities, and healthier employee populations Transparent reporting dashboards that track individual and population-level outcomes, including weight loss, medication usage, and program ROI We've worked with employers where 8085% of members stay engaged for 6+ months, and more than half continue engaging after medication has ended because they've built a trusted relationship with their coach

Your program includes: Initial medical evaluation metabolic assessment, lab work, and candidacy review Monthly monitoring dose titration, side effect management, and progress tracking Metabolic lab work HbA1c, lipid panel, kidney and liver function, fasting insulin Optional CGM during titration a 2-week continuous glucose monitor (patient-purchased OTC, $89) tracks your real glucose response to the medication, catches early hypoglycemia, and helps fine-tune dose and timing